# US 2025/0154483 A1 · Novel crispr dna and rna targeting enzymes and systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154483 A1
- Document ID: US20250154483A1
- Status: Published application
- Kind: A1
- Application number: 18/954,137
- Filed: 2024-11-20
- Published: 2025-05-15
- Earliest claimed: 2018-03-14
- Assignees: Arbor Biotechnologies, Inc.
- Applicants: Arbor Biotechnologies, Inc.
- Inventors: Elise Keston-Smith; David A. Scott; David R. Cheng; Winston X. Yan; Pratyusha Hunnewell; Jason Carte
- Web page: https://patentgrep.com/patent/US20250154483A1

## CPC

- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C07K 2319/85: containing an RNA binding domain
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids such as DNA. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.

## Claims

### Claim 1

An engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated (Cas) system comprising:
an RNA guide or a nucleic acid encoding the RNA guide, wherein the RNA guide comprises a direct repeat sequence, a spacer sequence capable of hybridizing to a target nucleic acid in a eukaryotic cell, and a tracrRNA; and
a RuvC nuclease domain-containing CRISPR-Cas effector protein or a nucleic acid encoding the RuvC nuclease domain-containing CRISPR-Cas effector protein, wherein the RuvC nuclease domain-containing CRISPR-Cas effector protein is capable of binding to the RNA guide and of targeting the target nucleic acid complementary to the spacer sequence;
wherein the RuvC nuclease domain-containing CRISPR-Cas effector protein comprises an amino acid sequence that is at least 80% identical to an amino acid sequence of any of SEQ ID NOs: 1-5, 7, 8, or 15-24.

### Claim 2 (depends on 1)

The system of claim 1, wherein:
(i) the RuvC nuclease domain-containing CRISPR-Cas effector protein comprises the amino acid sequence of any of SEQ ID NOs: 1-5, 7, 8, or 15-24;
(ii) the spacer sequence comprises 15 to 30 nucleotides;
(iii) the direct repeat sequence comprises a nucleotide sequence of:
(a) X1X2X3GNX6TX8X9GACACC (SEQ ID NO: 200), wherein X1 is A or G, X2 is A or C or G, X3 is C or G, X6 is A or C or T or U, N is any nucleic acid, X8 is C or G or Tor U, and X9 is C or G or T or U; or
(b) X1GX3GGTX7X8TTACAX14C (SEQ ID NO: 201), wherein X1 is C or G, X3 is G or Tor U, X7 is A or T or U, X8 is C or G, and X14 is A or C; or
(iv) any one of SEQ ID NOs: 9-11 or 25-34.

### Claim 3 (depends on 1)

The system of claim 1, wherein:
(i) the target nucleic acid is a single-stranded RNA;
(ii) the target nucleic acid is an RNA selected from the group consisting of an mRNA, a tRNA, a ribosomal RNA, a non-coding RNA, a lncRNA, or a nuclear RNA; or
(iii) the target nucleic acid is a DNA selected from the group consisting of chromosomal DNA, mitochondrial DNA, single-stranded DNA, or plasmid DNA.

### Claim 4 (depends on 1)

The system of claim 1, wherein the targeting of the target nucleic acid by the RuvC nuclease domain-containing CRISPR-Cas effector protein and the RNA guide results in a modification of the target nucleic acid, wherein:
(i) the modification in the target nucleic acid is a cleavage event;
(ii) the modification in the target nucleic acid is a nicking event; or
(iii) the target nucleic acid is comprised in a eukaryotic cell and the modification results in cell toxicity.

### Claim 5 (depends on 1)

The system of claim 1, wherein the RuvC nuclease domain-containing CRISPR-Cas effector protein includes one or more amino acid substitutions within the RuvC nuclease domain relative to any one of SEQ ID NOs: 1-5, 7, 8, or 15-24.

### Claim 6 (depends on 1)

The system of claim 1, wherein the RuvC nuclease domain is catalytically inactivated.

### Claim 7 (depends on 1)

The system of claim 1, wherein the RuvC nuclease domain-containing CRISPR-Cas effector protein is fused to a base-editing domain, an RNA methyltransferase, an RNA demethylase, a splicing modifier, a localization factor, or a translation modification factor.

### Claim 8 (depends on 7)

The system of claim 7, wherein the base-editing domain comprises Adenosine Deaminase Acting on RNA 1 (ADAR1), ADAR2, apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC), or activation-induced cytidine deaminase (AID).

### Claim 9 (depends on 7)

The system of claim 7, wherein the RuvC nuclease domain-containing CRISPR-Cas effector protein comprises:
(i) at least one nuclear localization signal (NLS); or
(ii) at least one nuclear export signal (NES).

### Claim 10 (depends on 1)

The system of claim 1, wherein the tracrRNA:
(a) comprises a nucleotide sequence provided in Table 6; or
(b) is encoded by a sequence or fragment thereof, listed in Table 7.

### Claim 11 (depends on 1)

An activated CRISPR complex comprising:
a CRISPR-Cas system of claim 1; and
a target nucleic acid bound to the RNA guide of the CRISPR-Cas system.

### Claim 12 (depends on 11)

A method of modifying a collateral nucleic acid, the method comprising contacting the collateral nucleic acid with an activated CRISPR complex of claim 11, wherein the collateral nucleic acid comprises a nucleic acid sequence that does not have sequence similarity to the target nucleic acid or a fragment thereof.

### Claim 13 (depends on 1)

A eukaryotic cell comprising the CRISPR-Cas system of claim 1.

### Claim 14 (depends on 1)

A method of targeting and editing a target nucleic acid, the method comprising contacting the target nucleic acid with a CRISPR-Cas system of claim 1.

### Claim 15 (depends on 1)

A method of cleaving a single-stranded DNA substrate, a single-stranded RNA substrate, or a double-stranded RNA substrate with the CRISPR-Cas system of claim 1, the method comprising contacting the single-stranded DNA substrate, single-stranded RNA substrate, or double-stranded RNA substrate with the CRISPR-Cas system, optionally wherein the single-stranded DNA substrate, single-stranded RNA substrate, or double-stranded RNA substrate lacks a protospacer adjacent motif (PAM) sequence protospacer flanking sequence (PFS) with a target nucleic acid.

### Claim 16 (depends on 11)

A method of non-specifically cleaving a collateral nucleic acid, the method comprising contacting the collateral nucleic acid with an activated CRISPR complex of claim 11, wherein the collateral nucleic acid is a single-stranded DNA, single-stranded RNA, or double-stranded RNA, and wherein the collateral nucleic acid comprises a nucleic acid sequence that does not have sequence similarity to the target nucleic acid.

### Claim 17 (depends on 1)

A method of detecting a target RNA in a sample, the method comprising:
(a) contacting the sample with the CRISPR-Cas system of claim 1 and a labeled detector RNA, wherein hybridization of the RNA guide to the target RNA causes a cleavage of the labeled detector RNA; and
(b) measuring a detectable signal produced by cleavage of the labeled detector RNA, thereby detecting the target RNA in the sample.

### Claim 18 (depends on 1)

A method of modifying a RNA molecule, the method comprising contacting the RNA molecule with a system of claim 1.
